Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
Solli, Kristin Klemmetsby; Opheim, Arild; Latif, Zill-E-Huma; Krajci, Peter; Saltyte Benth, Jurate; Kunoe, Nikolaj; Tanum, Lars Håkon Reiestad
Journal article, Peer reviewed
Published version
Permanent lenke
https://hdl.handle.net/10642/9766Utgivelsesdato
2020-12-18Metadata
Vis full innførselSamlinger
Originalversjon
Solli KK, Opheim A, Latif HL, Krajci P, Saltyte Benth J, Kunoe, Tanum L. Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone. Addiction. 2020 https://doi.org/10.1111/add.15378Sammendrag
Background and aim: Extended-release naltrexone (XR-NTX) is an underused treatment option for opioid dependence, today only available in a few countries in the world. Although effective, safe and feasible in short-term treatment, long-term data are scarce and there is no recommendation for required treatment length. The aims of the study were to determine the perceived need of long-term XR-NTX treatment and to examine long-term treatment outcomes. Design: In this prospective cohort study, following a parent 1-year study of XR-NTX, participants received treatment with XR-NTX at their own discretion for a maximum of 104 weeks. Setting: Five urban, outpatient addiction clinics in Norway. Participants: Opioid-dependent adults 18-60 years old (n=50) already participating in the parent study. Intervention: XR-NTX administrated as intra-muscular injections (380 mg) every 4 weeks. Measurements: Time in the study, use of opioids and other illicit substances, opioid craving, and treatment satisfaction reported every 4 weeks. Findings: Among 58 participants who completed the 1-year parent study, 50 chose to continue the treatment with XR-NTX. Median prolonged treatment time was 44.0 weeks (95% CI: 25.5-62.5), ranging from 8 to 104 weeks. Most participants (35, 70%) reported no relapse to opioid use during treatment while a subgroup (15, 30%) reported relapses to opioids during the study. Scores for mean treatment satisfaction and recommending treatment to others were very high (>9) and mean opioid craving score was very low (<1) on a scale ranging from 0 to 10. Conclusions: Extended-release naltrexone (XR-NTX) was well tolerated in long-term treatment of opioid dependent individuals in Norway already in XR-NTX treatment. On average, the participants chose to continue treatment for almost 1 year beyond the initial 9 to 12 months of treatment. Participants reported high treatment satisfaction and 70% showed no relapse to opioids during the treatment period.
Utgiver
WileySerie
Addiction;Tidsskrift
Addiction
Med mindre annet er angitt, så er denne innførselen lisensiert som Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License
Beslektede innførsler
Viser innførsler beslektet ved tittel, forfatter og emneord.
-
Fecal microbiota profiles in treatment-naive pediatric inflammatory bowel disease ? associations with disease phenotype, treatment, and outcome
Olbjørn, Christine; Småstuen, Milada Cvancarova; Thiis-Evensen, Espen; Nakstad, Britt; Vatn, Morten H; Jahnsen, Jørgen; Ricanek, Petr; Vatn, Simen Svendsen; Moen, Aina Elisabeth Fossum; Tannæs, Tone Møller; Lindstrøm, Jonas Christoffer; Söderholm, Johan D.; Halfvarson, Jonas; Gomollón, Fernando; Casén, Christina; Karlsson, Magdalena Kauczynska; Kalla, Rahul; Adams, Alex T.; Satsangi, Jack; Perminow, Gøri Margrete (Clinical and Experimental Gastroenterology;Volume 12, Journal article; Peer reviewed, 2019-12-13)Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal ... -
Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
Midgard, Håvard; Finbråten, Ane-Kristine; Malme, K.B.; Berg-Pedersen, Riikka Mari; Tanum, Lars Håkon Reiestad; Inge Christoffer, Olsen; Bjørnestad, Ronny; Dalgard, Olav (Trials;21, Article number: 524 (2020), Journal article; Peer reviewed, 2020-06-15)Background: Scaled-up direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection among people who inject drugs (PWID) is crucial to reach the World Health Organization HCV elimination targets within 2030. ... -
Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach
Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan; Hoff, Geir; Oshaug, Arne; Aas, Eline (European Journal of Health Economics;, Journal article; Peer reviewed, 2019-11-09)New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. ...